Skip to content

Tedizolid Suppressive Antimicrobial Therapy in a Reference Center

Tedizolid Suppressive Antimicrobial Therapy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04662736
Acronym
TediSAT
Enrollment
17
Registered
2020-12-10
Start date
2021-02-01
Completion date
2021-04-01
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Joint Infection

Keywords

bone and joint infection, tedizolid, suppressive antibiotic therapy

Brief summary

the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.

Interventions

OTHERpatients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy

description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapybetween 2016 and 2021proportion of patients having tedizolid as a suppressive antibiotic therapy
rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic2 yearsproportion of patients having a failure under tedizolid as a suppressive antibiotic therapy
rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressivethrough study completion, an average of 1 yearproportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy
Description of patients having had a BJI/PJI treated with tedizolid as a suppressive2 yearstype of patients: age, CMI, comorbidities...
Description of BJI/PJI treated with tedizolid as a suppressive2 yearsimplant or prothese or not, acute/ chronic, bacteriology

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026